ATC codes:
H02AB02
EMLc
Indication
Allergic or hypersensitivity conditions of unspecified type
ICD11 code:
4A8Z
INN
Dexamethasone
Medicine type
Chemical agent
List type
Core
(EML)
(EMLc)
(EMLc)
Formulations
Oral > Liquid:
0.5 mg per 5 mL (as sodium phosphate)
(EMLc)
;
2 mg per 5 mL (as sodium phosphate)
Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
Oral > Solid > tablet: 0.5 mg (as dexamethasone base) ; 0.75 mg (as dexamethasone base) ; 1.5 mg (as dexamethasone base) ; 2 mg (as dexamethasone base) ; 4 mg (as dexamethasone base)
Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
Oral > Solid > tablet: 0.5 mg (as dexamethasone base) ; 0.75 mg (as dexamethasone base) ; 1.5 mg (as dexamethasone base) ; 2 mg (as dexamethasone base) ; 4 mg (as dexamethasone base)
EML status history
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Read more
about patents.
Wikipedia
DrugBank
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:
- the addition of dexamethasone oral liquid 0.5 mg/5 mL (as sodium phosphate) to the EMLc;
- the addition of dexamethasone tablets 0.5 mg, 0.75 mg, 1.5 mg and 4 mg (as dexamethasone base) to the EML and EMLc;
- to modify the listings to reflect the amount of dexamethasone in terms of dexamethasone salt or dexamethasone base.